Data report on inflammatory C–C chemokines among insulin-using women with diabetes mellitus and breast cancer

Data in Brief

Jeffrey P. Hammel¹  Dan P. Gaile²  Zachary A.P. Wintrob³  Erin E. Davis³  Alice C. Ceacareanu³  George K. Nimako³  Zahra S. Fayazi³  Alan Forrest⁴ 

[1] Cleveland Clinic, Dept. of Biostatistics and Epidemiology, 9500 Euclid Ave., Cleveland, OH 44195, United States;State University of New York at Buffalo, Dept. of Biostatistics, 718 Kimball Tower, Buffalo, NY 14214, United States;State University of New York at Buffalo, Dept. of Pharmacy Practice, NYS Center of Excellence in Bioinformatics and Life Sciences, 701 Ellicott Street, Buffalo, NY 14203, United States;The UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, Campus Box 7569, Chapel Hill, NC 27599, United States;

关键词: Inflammation;    Inflammatory cytokines;    C-C chemokines;    CCL-2;    CCL-3;    CCL-4;    CCL-5;    Insulin;    Breast cancer;    Diabetes;    Tumor-associated macrophages;    Cancer prognosis;   

DOI  :  10.1016/j.dib.2017.02.045

来源: DOAJ

【 摘 要 】

Injectable insulin use may interfere with pro-inflammatory cytokines’ production and, thus, play a role in the activation of tumor-associated macrophages - a process mainly influenced by inflammatory C–C chemokines. The data presented shows the relationship between pre-existing use of injectable insulin in women diagnosed with breast cancer and type 2 diabetes mellitus, the inflammatory C–C chemokine profiles at the time of breast cancer diagnosis, and subsequent cancer outcomes. A Pearson correlation analysis stratified by insulin use and controls is also provided. We present the observed relationship between the investigated C–C chemokines and between each of these biomarkers and previously reported adipokines levels in this study population [1].

【 授权许可】

Unknown